Influence of Pharmacogenomics Polymorphism and Non- Genetics Factors on Allopurinol-Induced Cutaneous Adverse Drug Reactions in Thai Patients Running title: Genetics of Allopurinol-induced CADRs in Thais-Reference-Cited by-同舟云学术

Influence of Pharmacogenomics Polymorphism and Non- Genetics Factors on Allopurinol-Induced Cutaneous Adverse Drug Reactions in Thai Patients Running title: Genetics of Allopurinol-induced CADRs in Thais

Published:2023-05-30 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Sornsamdang Gaidganok¹,Satapornpong Patompong²,Jinda Pimonpan¹,Jantararoungtong Thawinee¹,Koomdee Napatrupron¹,Tempark Therdpong³,Klaewsongkram Jettanong³,Rerkpattanapipat Ticha¹,Rerknimitr Pawinee³,Tuchinda Papapit¹,Chularojanamontri Leena¹,Tovanabutra Napatra⁴,Chanprapaph Kumutnart¹,Disphanurat Wareeporn⁵,Chakkavittumrong Panlop⁵,Srisuttiyak Chutika⁶,Srinoulpras Yuttana¹,John Shobana¹,Biswas Mohitosh¹,Sukasem Chonlaphat¹

Affiliation:

1. Mahidol University

2. Rangsit University

3. Chulalongkorn University

4. Chiang Mai University

5. Thammasat University

6. Phramongkutklao College of Medicine

Abstract

Abstract Allopurinol is causing substantial morbidity and mortality particularly in Asian population by producing cutaneous adverse drug reactions (cADRs). The goal of this study was to identify genetic biomarkers of single nucleotide polymorphisms (SNPs) for allopurinol induced cADRs among Thai patients. We conducted a case-control association study after enrolling 57 Thai patients with allopurinol induced cADRs and 101 allopurinol tolerant controls. Genetic biomarkers and associated SNPs located on chromosome 6p21 were examined by TaqMan® SNP genotyping assays in both case and controls. Out of 15 SNPs in nine genes, four combined SNPs (rs3099844 of HCP5; rs9263726 of PSORS1C1; rs9263733 of POLR2LP and rs9263745 of CCHCR1) were significantly associated with allopurinol induced cADRs compared to tolerant controls (OR 3.2; 95% CI 24.2-266.8; P = 1.9x10− 24). Overall sensitivity, specificity, positive predictive value and negative predictive value of these combinations were 84%, 94%, 9% and 100%, respectively. The SNPs were not in absolute linkage disequilibrium with HLA-B*58:01, however, the variant alleles of these SNPs combination were detected in 89.5% (51/57) of the cases. The findings suggest that these SNPs could be used as an alternative novel biomarker in predicting cADRs in patients taking allopurinol especially in those with absence of HLA-B*58:01 allele but still experiencing cADRs.

Publisher

Research Square Platform LLC

Reference39 articles.

1. Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, Lin Y-L, Lan J-L, Yang L-C, Hong H-S et al. HLA-B*5801 allele as a genetic marker for severe cu-taneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 4134–4139, doi:10.1073/pnas.0409500102.

2. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population;Tassaneeyakul W;Pharmacogenet Genomics,2009

3. HLA Association with Drug-Induced Adverse Reactions;Fan W-L;J Immunol Res 2017,2017

4. Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation;Sukasem C;Asian Pac J allergy Immunol,2014

5. HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand;Sukasem C;Front Pharmacol,2016